Rein Therapeutics, Inc. SEC filings RNTX
Rein Therapeutics, Inc. has 525 filings in SEC EDGAR's recent list, going back to Dec 3, 2007. Its latest annual report, Form ARS, was filed on Jun 8, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 4, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jun 8, 2026 | — |
| DEF 14A | Proxy statement | Jun 8, 2026 | Jul 20, 2026 |
| PRE 14A | Preliminary proxy statement | May 28, 2026 | Jul 20, 2026 |
| DEFA14A | Additional proxy material | Jul 11, 2025 | — |
| DEFA14A | Additional proxy material | Jun 24, 2025 | — |
| DEFA14A | Additional proxy material | May 12, 2025 | — |
| DEF 14A | Proxy statement | May 12, 2025 | Jun 24, 2025 |
| DEFA14A | Additional proxy material | Jul 9, 2024 | — |
| DEF 14A | Proxy statement | Jul 9, 2024 | Aug 20, 2024 |
| DEFA14A | Additional proxy material | Jan 31, 2024 | — |
| DEF 14A | Proxy statement | Jan 29, 2024 | Feb 28, 2024 |
| PRE 14A | Preliminary proxy statement | Jan 19, 2024 | Jan 19, 2024 |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 15, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2022 | Jun 15, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2021 | — |
| DEF 14A | Proxy statement | Apr 28, 2021 | Jun 15, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2021 | Jun 15, 2021 |
| DEFA14A | Additional proxy material | Apr 28, 2020 | — |
| DEF 14A | Proxy statement | Apr 28, 2020 | Jun 17, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2020 | Jun 17, 2020 |
| DEFA14A | Additional proxy material | Apr 30, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 19, 2019 |
| DEFA14A | Additional proxy material | Apr 30, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 21, 2018 |
Showing 25 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNTX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1420565
- Former names
- Aileron Therapeutics, Inc. (until Dec 9, 2024); AILERON THERAPEUTICS INC (until Mar 29, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.